Inhibition of hepatoma 22 tumor by liquiritigenin

Phytotherapy Research

Volumn 24, Issue 6, 2010, Pages 827-833

  Zhou, Ming ^a   Higo, Haruo ^a   Cai, Yunqing ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Hepatoma; Liquiritigenin; Malonaldehyde

Indexed keywords

CYCLOPHOSPHAMIDE; LIQUIRITIGENIN; MALONALDEHYDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CANCER CELL DESTRUCTION; CANCER INHIBITION; CANCER MODEL; CANCER TISSUE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; ELECTRON MICROSCOPY; HISTOPATHOLOGY; IN VIVO STUDY; LIVER CELL CARCINOMA; LIVER STRUCTURE; MALE; MOUSE; NONHUMAN; ORGAN SIZE; SPLEEN SIZE; THYMUS; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BODY WEIGHT; CARCINOMA, HEPATOCELLULAR; CELL NUCLEUS; FLAVANONES; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED ICR; NEOPLASM TRANSPLANTATION; ORGAN SIZE; SPLEEN; THYMUS GLAND; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 77953243584     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.3024     Document Type: Article

References (45)

1. Adhami VM, Ahmad N, Mukhtar H. 2003. Molecular targets for green tea in prostate cancer prevention. J Nutr 133: 2417S-2424S.
2. Armstrong B, Doll R. 1975. Environmental factors a nd cancer incidence and mortality in different countries, with special reference to dietary practices. Int J Cancer 15: 617-631.
3. Chang KL, Kung ML, Chow NH, Su SJ. 2004. Genistein arrests hepatoma cells at G2/M phase: involvement of ATM activation and upregulation of p21waf1/cip1 and Wee1. Biochem Pharmacol 67: 717-726.
4. Cini M, Fariello RG, Bianchetti A, Moretti A. 1994. Studies on lipid peroxidation in the rat brain. Neurochem Res 19: 283-288. (Pubitemid 24054798)
5. Cummins J, McCulloch P. 2001. ASCOT: a comprehensive clinical database for gastro-oesophageal cancer surgery. Eur J Surg Oncol 27: 709-713.
6. Falcão MJ, Pouliquem YB, Lima MA, Gramosa NV, Costa-Lotufo LV, Militão GC, Pessoa C, de Moraes MO, Silveira ER. 2005. Cytotoxic flavonoids from Platymiscium floribundum. J Nat Prod 68: 423-426.
7. Farazi PA, DePinho RA. 2006. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6: 674-687.
8. Forner A, Hessheimer AJ, Isabel Real M, Bruix J. 2006. Treatment of hepatocellular carcinoma. Crit Rev Oncol Hematol 60: 89-98.
9. Gaweł S, Wardas M, Niedworok E, Wardas P. 2004. Malondialdehyde (MDA) as a lipid peroxidation marker. Wiad Lek 57: 453-455.
10. Hollman PC, Katan MB. 1997. Absorption, metabolism and health effects of dietary flavonoids in man. Biomed Pharmacother 51: 305-310.
11. Hou Z, Lambert JD, Chin KV, Yang CS. 2004. Effects of tea polyphenols on signal transduction pathways related to cancer chemoprevention. Mutat Res 555: 3-19.
12. Jahromi MA, Ray AB. 1993. Antihyperlipidemic effect of flavonoids from Pterocarpus marsupium. J Nat Prod 56: 989-994.
13. Jiang X, Patterson NM, Ling Y, Xie J, Helferich WG, Shapiro DJ. 2008. Low Concentrations of the Soy Phytoestrogen Genistein Induce Proteinase Inhibitor 9 and Block Killing of Breast Cancer Cells by Immune Cells. Endocrinology 11: 5366-5373.
14. Kale A, Gawande S, Kotwal S. 2008. Cancer phytotherapeutics: role for flavonoids at the cellular level. Phytother Res 22: 567-577.
15. Kamei J, Saitoh A, Asano T, Nakamura R, Ichiki H, Iiduka A, Kubo M. 2005. Pharmacokinetic and pharmacodynamic profiles of the antitussive principles of Glycyrrhizae radix (licorice), a main component of the Kampo preparation Bakumondo-to (Mai-men-dong-tang). Eur J Pharmacol 507: 163-168.
16. Kandaswami C, Lee LT, Lee PP, Hwang JJ, Ke FC, Huang YT, Lee MT. 2005. The antitumor activities of flavonoids. In Vivo 19: 895-909.
17. Kaneuchi M, Sasaki M, Tanaka Y, Sakuragi N, Fujimoto S, Dahiya R. 2003. Quercetin regulates growth of Ishikawa cells through the suppression of EGF and cyclin D1. Int J Oncol 22: 159-164.
18. Kawashima S. 2004.Malfunction of vascular control in lifestyle-related diseases: endothelial nitric oxide (NO) synthase/NO system in atherosclerosis. J Pharmacol Sci 96: 411-419.
19. Keli SO, Hertog MG, Feskens EJ, Kromhout D. 1996. Dietary flavonoids, antioxidant vitamins, and incidence of stroke: the Zutphen study. Arch Intern Med 156: 637-642.
20. Kim YW, Ki SH, Lee JR, Lee SJ, Kim CW, Kim SC, Kim SG. 2006. Liquiritigenin, an aglycone of liquiritin in Glycyrrhizae radix, prevents acute liver injuries in rats induced by acetaminophen with or without buthionine sulfoximine. Chem Biol Interact 161: 125-138.
21. Kim YW, Zhao RJ, Park SJ, Lee JR, Cho IJ, Yang CH, Kim SG, Kim SC. 2008. Anti-inflammatory effects of liquiritigenin as a consequence of the inhibition of NF-kappaB-dependent iNOS and proinflammatory cytokines production. Br J Pharmacol 154: 165-173.
22. Lee WR, Shen SC, Lin HY, Hou WC, Yang LL, Chen YC. 2002. Wogonin and fisetin induce apoptosis in human promyeloleukemic cells, accompanied by a decrease of reactive oxygen species, and activation of caspase 3 and Ca(2+)-dependent endonuclease. Biochem Pharmacol 63: 225-236.
23. Mishra KP, Chanda S, Karan D, Ganju L, Sawhney RC. 2008. Effect of Seabuckthorn (Hippophae rhamnoides) flavone on immune system: an in-vitro approach. Phytother Res 11: 1490-1495.
24. Misthos P, Katsaragakis S, Milingos N, Kakaris S, Sepsas E, Athanassiadi K, Theodorou D, Skottis I. 2005. Postresectional pulmonary oxidative stress in lung cancer patients. The role of one-lung ventilation. Eur J Cardiothorac Surg 27: 379-383.
25. Ness AR, Powles JW. 1997. Fruit and vegetables, and cardiovascular disease: a review. Int J Epidemiol 26: 1-13.
26. Ogawa Y, Oku H, Iwaoka E, Iinuma M, Ishiguro K. 2007. Allergy-preventive flavonoids from Xanthorrhoea hastilis. Chem Pharm Bull 55: 675-678.
27. Ohtake N, Suzuki R, Daikuhara H, Nakai Y, Yamamoto M, Amagaya S, Ishige A, Sasaki H, Komatsu Y, Fukuda, K, Hayashi S. 2000. Modulation of lung local immune responses by oral administration of a herbal medicine Sho-saiko-to. Int J Immunopharmacol 22: 419-430.
28. Pacher P, Obrosova IG, Mabley JG, Szabó C. 2005. Role of nitrosative stress and peroxynitrite in the pathogenesis of diabetic complications. Emerging new therapeutical strategies. Curr Med Chem 12: 267-275. (Pubitemid 40305619)
29. Pang R, Tse E, Poon RT. 2006. Molecular pathways in hepatocellular carcinoma. Cancer Lett 240: 157-169.
30. Parkin DM, Bray F, Ferlay J, Pisani P. 2005. Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108.
31. Rots MG, Curiel DT, Gerritsen WR, Haisma HJ. 2003. Targeted cancer gene therapy: the flexibility of adenoviral gene therapy vectors. J Control Release 87: 159-165.
32. Schmitt G, Wambersie A. 1990. Review of the clinical results of fast neutron therapy. Radiother Oncol 17: 47-56. (Pubitemid 20052460)
33. Shimada M, Takenaka K, Kawahara N, Yamamoto K, Shirabe K, Maehara Y, Sugimachi K. 1996. Chemosensitivity in primary liver cancers: evaluation of the correlation between chemosensitivity and clinicopathological factors. Hepatogastroenterology 43: 1159-1164. (Pubitemid 26358508)
34. Shimizu M, Deguchi A, Lim JT, Moriwaki H, Kopelovich L, Weinstein IB. 2005. (-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells. Clin Cancer Res 11: 2735-2746.
35. Shin YW, Bae EA, Lee B, Lee SH, Kim JA, Kim YS, Kim DH. 2007. In vitro and in vivo antiallergic effects of Glycyrrhiza glabra and its components. Planta Med 73: 257-261.
36. Steinmetz KA, Potter JD. 1996. Vegetables, fruit, and cancer prevention: a review. J Am Diet Assoc 96: 1027-1039.
37. Sullivan PG, Brown MR. 2005. Mitochondrial aging and dysfunction in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 29: 407-410.
38. Suzui M, Masuda M, Lim JT, Albanese C, Pestell RG, Weinstein IB. 2002. Growth inhibition of human hepatoma cells by acyclic retinoid is associated with induction of p21(CIP1) and inhibition of expression of cyclin D1. Cancer Res 62: 3997-4006.
39. Takiguchi N, Saito N, Nunomura M, Kouda K, Oda K, Furuyama N, Nakajima N. 2001. Use of 5-FU plus hyperbaric oxygen for treating malignant tumors: evaluation of antitumor effect and measurement of 5-FU in individual organs. Cancer Chemother Pharmacol 47: 11-14.
40. Tang ZY. 2002. Small hepatocellular carcinoma: current status and prospects. HBPD INT 1: 349-353.
41. Torchilin VP. 2000. Drug targeting. Eur J Pharm Sci 11: S81-S91.
42. Yagi K. 1987. Lipid peroxides and human diseases. Chem Phys Lipids 45: 337-351.
43. Yao Z, Lu R, Jia J, Zhao P, Yang J, Zheng M, Lu J, Jin M, Yang H, Gao W. 2006. The effect of tripeptide tyroserleutide (YSL) on animal models of hepatocarcinoma. Peptides 27: 1167-1172.
44. Yu ES, Min HJ, An SY, Won HY, Hong JH, Hwang ES. 2008. Regulatory mechanisms of IL-2 and IFNgamma suppression by quercetin in T helper cells. Biochem Pharmacol 76: 70-78.
45. Zhang SP, Zhou YJ, Liu Y, Cai YQ. 2009. Effect of liquiritigenin, a flavanone existed from Radix glycyrrhizae on proapoptotic in SMMC-7721 cells. Food Chem Toxicol 47: 693-701.